Compare GFL Environmental Inc. Subordinate voting shares no par value (GFL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GFL Environmental Inc. Subordinate voting shares no par value vs Novavax Inc — how do they compare? GFL Environmental Inc. Subordinate voting shares no par value trades at $42.2 (market cap $18.33B), while Novavax Inc trades at $11.06 (market cap $1.85B). The key difference: GFL Environmental Inc. Subordinate voting shares no par value is far larger — about 9.9× Novavax Inc's market cap, and GFL Environmental Inc. Subordinate voting shares no par value pays a 0.16% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GFL Environmental Inc. Subordinate voting shares no par value for 0 Days and Novavax Inc for 59 Days on average.
| GFL | NVAX | |
|---|---|---|
Market Cap | $18.33B | $1.85B |
Volume | 2,954,733 | 8,362,562 |
Sector | Industrials | Health |
52-Week High | $46.51 | $12.56 |
52-Week Low | $33.54 | $6.22 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $25.33B | $1.43B |
Dividend Yield | 0.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental provides environmental services across Canada and the United States. Its operations include solid waste management and other waste and environmental solutions.
Read more on GFL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
